Search Results - solid+tumors

7 Results Sort By:
Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)
UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...
Published: 6/27/2024   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF
Category(s): Therapeutics > Oncology
Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024   |   Inventor(s): Lili Yang
Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
FIBP Knockout Potentiates Therapeutic Effects of T-cell Based Therapies in Solid Tumors
Abstract: Despite recent breakthroughs in cancer immunotherapy, T-cell based therapies achieve limited efficacy in solid tumors. Immunosuppression, antigen escape and physical barriers to entry into solid tumors are issues faced. Identifying regulators in T-cell dysfunction remains challenging due to limitations of current screening platforms.  Using...
Published: 4/8/2024   |   Inventor(s): Peng Jiang, Yu Zhang
Keywords(s): adoptive cell therapy, Cancer Immunotherapy, cholesterol metabolism, Computational Model, FGF1 Intracellular Binding Protein, FIBP, Jiang, solid tumors, T-Cell based Therapy, T-Cell Resilience
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
PIM-Targeted PROTACs
Abstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical...
Published: 4/8/2024   |   Inventor(s): John Brognard, Rolf Swenson, Pedro Torres-Ayuso, Venkatareddy Sabbasani, Dawid Mehlich, Noel Warfel
Keywords(s): anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
Abstract: Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains...
Published: 4/8/2024   |   Inventor(s): Giovanna Tosato, Michael Diprima, Harald Schwalbe, Alix Troster, Nathalie Jores, Denis Kudlinzki
Keywords(s): colorectal cancer, Eph Kinase Inhibitors, Eph-related cancers, Ephrin, NVP-BHG712, Regioisomer NVP-Iso, small molecule, solid tumors, Tosato, Tyrosine kinase inhibitors
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Screening and Treatment Methods for Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
Researchers at TGen, in collaboration with the University of British Columbia, have developed methods and compositions for screening for Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) in a patient based on the genomic profile of a biological sample to enable earlier diagnosis and more effective treatment than is currently available for...
Published: 9/13/2024   |   Inventor(s): Jeffrey Trent, Pilar Ramos, William Hendricks, Anthony "Tony" Karnezis, David Huntsman, David Craig, Hongwei "Holly" Yin, Yemin Wang
Keywords(s): Small Cell Carcinoma, Solid Tumors
Category(s): Genomics/Genetics